Adlai Nortye Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANL research report →
Range $20 – $32
Price Chart
About the company
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials.
- CEO
- Yang Lu
- IPO
- 2023
- Employees
- 109
- HQ
- Grand Cayman, US
Get TickerSpark's AI analysis on ANL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $728.26M
- P/E
- -7.02
- PEG
- -0.88
- P/S
- 37.00
- P/B
- 1.02
- EV/EBITDA
- -28.99
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -113.28%
- Net Margin
- -114.48%
- ROE
- -21.82%
- ROIC
- -9.23%
Latest fiscal year · YoY change
- Revenue
- $5.00M+0.0%
- Gross Profit
- $5.00M+0.0%
- Op Income
- $-35,698,000
- Net Income
- $-35,528,000+31.5%
- EPS
- $-3.33+31.9%
- OCF Growth
- +35.3%
- FCF Growth
- +35.1%
- 52W High
- $17.25
- 52W Low
- $0.88
- 50D MA
- $11.67
- 200D MA
- $8.24
- Beta
- 1.17
- RSI (14)
- 59
- Avg Volume
- 174.66K
No earnings-call transcripts are available for ANL yet.
- Free Float
- 71.2%
- Shares Outstanding
- 53.08M
- Float Shares
- 12.60M
of shares held by institutions
4 13F filers
Held by 2 ETFs
Biggest fund positions in ANL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Birgerson Lars Erik | other | 0 |
| Mar 18, 26 | Sawhney Roger | other | 0 |
| Mar 18, 26 | Sawhney Roger | other | 4,162 |
| Jun 10, 26 | Ji Ping | other | 136,667 |
| May 28, 26 | Ye Xiaofeng | other | 0 |
| May 28, 26 | Ye Xiaofeng | other | 0 |
| Apr 1, 22 | Ye Xiaofeng | other | 25,000 |
| Sep 8, 20 | Ye Xiaofeng | other | 66,667 |
| Nov 1, 20 | Ye Xiaofeng | other | 2,584 |
| Mar 18, 26 | Tse Alan Ming Lun | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANL coverage
Recent articles, reports, and earnings notes.
No research on ANL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANL report →Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
zacks.com · Aug 18
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
globenewswire.com · Aug 14
Adlai Nortye (ANL) to Announce Quarterly Earnings on Thursday
defenseworld.net · Aug 5
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
globenewswire.com · Aug 3
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
globenewswire.com · Jul 16
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
globenewswire.com · Jul 13
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
zacks.com · May 20
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
zacks.com · May 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.